Monthly Archives: August 2009

Lilly’s ImClone Makes NYC Its Home Base

Yet another pharma firm is going to be calling New York City home. Late last month, Lilly announced that it would lease space at the Alexandria Center, to house the new research headquarters for ImClone Systems. ImClone will be the anchor tenant at Alexandria’s newest life science destination located in Manhattan’s East Side life science/medical […]
Posted in Strategy | Tagged , , , , , , | 1 Comment

Feds Publically Spank Bad Investigators

Image via Wikipedia FDA, late on Friday, announced that it would ramp up efforts to keep naughty investigators from working for companies with approved or pending drug applications. “The FDA views any deviation from its high standards for developing or marketing drugs and devices as a potential threat to patient safety and public health,” stated […]
Posted in Regulatory | Tagged , , , , | Leave a comment

FDA Strengthens Warnings on TNF Inhibitors

On Tuesday, FDA announced that makers of tumor necrosis factor (TNF) blockers must change their labels to include boxed warnings for “increased risk of lymphoma and other malignancies in children and adolescents.” That’s in addition to the current box warning that the drugs might lead to cancer. TNF blockers (or inhibitors) are used to reduce […]
Posted in News | Tagged , , , , , , | 1 Comment

Avastin Gets Green Light for Use in Kidney Cancer

Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and […]
Posted in News | Tagged , , , , , , , | Leave a comment

Lilly Sales Force Buyouts Revealed

Image via Wikipedia Lilly, on Tuesday, announced that it will offer 4,000 sales reps a buyout in hopes of reducing its sales force by 300 before year’s end. According to a Lilly spokesperson, this is a voluntary exit program for eligible sales force professionals in its diabetes, neuroscience, and osteoporosis business units. Reps have the […]
Posted in News | Tagged , , , , | Leave a comment
  • Categories

  • Meta